Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: audioWCAG2.1 who wrote (63036)	3/18/2025 8:17:12 AM
From: erickerickson	1 Recommendation Recommended By erippetoe Read Replies (1) \| Respond to of 63304

SRPT: investorrelations.sarepta.com Unfortunately true, a patient died due to acute liver failure. This is a known risk and there is a comorbidity. SRPT is not a one-trick-pony though, so I'll just ride this one out. ------------- ...has passed away following treatment with ELEVIDYS, having suffered acute liver failure. Acute liver injury is a known possible side effect of ELEVIDYS and other AAV-mediated gene therapies...acute liver failure (ALF) leading to death represents a severity of acute liver injury not previously reported for ELEVIDYS, which to date has been used to treat more than 800 patients in clinical trials or as a prescribed therapy. In addition, testing revealed this patient had a recent cytomegalovirus (CMV) infection which was identified by the treating physician as a possible contributing factor. CMV can infect and damage the liver, a condition known as CMV hepatitis. -----------------